Pharmaceutical compositions and method for prophylaxis and therapy of radical-mediated cell damage

US6172056A · kind A · utility

Assignee

• Jenapharm GmbH & Co. KG · DE

Inventors

• Peter Droescher · Weimar, DE
• Bernd Menzenbach · Jena, DE
• Kurt Ponsold · Jena, DE
• Bernd Undeutsch · Jena, DE
• Michael Oettel · Jena, DE
• Wolfgang Romer · Jena, DE
• Gunter Kaufmann · Jena, DE
• Jens Schroeder · Kiel, DE

Key dates

• Filing date: May 9, 1996
• Grant date: Jan 9, 2001
• Expiry date: May 9, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/575
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The method of prophylaxis and therapy of radical-mediated cell damage includes administering an effective amount of at least one steroid and at least one pharmaceutical adjuvant to a human being. The at least one steroid is selected from the group consisting of ent-estradiol, 17.alpha.-estradiol, 8-dehydro-estradiol, 8-dehydro-17.alpha.-estradiol, 8(14)-dehydroestradiol, 6,8-didehydro-17.alpha.-estradiol, 6-dehydroestriol, 9(11)-dehydroestriol, 20-hydroxymethyl-3-hydroxy-19-norpregna-1,3,5(10)-triene, 14.alpha., 15.alpha.-methylene-8-dehydroestradiol, 14.alpha., 15.alpha.-methylene-estradiol, 2-hydroxy-estradiol-3-methyl ether, 3-hydroxy-1,3,5(10)-estratriene-17S-spirooxirane, 3-hydroxy-1,3,5(10),9(11)-estratetraene-17S-spirooxirane, and 14.beta.,15.beta.-methylene-8-dehydroestradiol. This method strongly inhibits changes in cells and tissues, such as lipid peroxidation and oxidation of low-density lipoprotein (LDL) cholesterol, triggered by reaction oxygen species, free oxygen radicals and other forms of radicals and thus reduces attendant irreversible membrane and endothelial damage.